IN-BOEHRINGER-INGELHEIM
7.12.2022 10:40:38 CET | Business Wire | Press release
The DINAMO Phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with empagliflozin compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes.1 When empagliflozin was added to other baseline treatments (diet, exercise, metformin and/or insulin) HbA1c was reduced by 0.84% compared with placebo at week 26 (95% CI –1.50 to –0.19; P=0.012).1 The results were presented today at the International Diabetes Federation (IDF) World Diabetes congress 20221, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221207005405/en/
The DINAMO (DIabetes study of liNAgliptin and eMpagliflozin in children and adOlescents) trial included youth aged 10-17 years with type 2 diabetes and HbA1c ≥6.5% and ≤10.5%. Participants were randomly assigned treatment with empagliflozin (10 or 25 mg) (n=52), linagliptin (5 mg) (n=53) or placebo (n=53) once daily. All participants were treated with diet and exercise plus, when appropriate, metformin and/or insulin.1
The overall safety data was generally consistent with previous findings in adults with type 2 diabetes, confirming the well-established safety profile of both Jardiance® (empagliflozin) and Trajenta® (linagliptin).1
“Across the lifespan, we know that people living with type 2 diabetes have a high risk for many diabetes complications, so it’s important to recognize and treat diabetes early in its course,” said Lori Laffel, M.D., Principal Investigator of the DINAMO study and Chief of the Pediatric, Adolescent, and Young Adult Section at the Joslin Diabetes Center and Professor of Pediatrics at Harvard Medical School. “Today’s results from the DINAMO global clinical trial demonstrated that the SGLT2 inhibitor empagliflozin compared with placebo significantly improved overall blood sugar control in children and adolescents with type 2 diabetes. These findings are particularly important given the need for more therapeutic options, especially oral agents, to manage type 2 diabetes in young people as, to date, metformin is the only globally available oral treatment for youth.”
A secondary endpoint from the trial showed that at week 26, empagliflozin reduced fasting plasma glucose (–35.2 mg/dL; P=0.0035).1
“With more than 41,000 new cases worldwide annually, type 2 diabetes in today’s young people is a global public health issue, especially in light of rise of risk factors such as obesity,” said Lykke Hinsch Gylvin, M.D., Chief Medical Officer at Boehringer Ingelheim. “The clinically meaningful benefit and consistent safety profile demonstrated with empagliflozin in the DINAMO trial is an encouraging outcome for the vulnerable population of children and adolescents.”
“The rise in the prevalence of type 2 diabetes in the pediatric population highlights a clear unmet need,” said Jeff Emmick, M.D., Ph.D., Vice President, Product Development, Eli Lilly & Company. “Having overcome the challenges in recruitment and design that pediatric trials tend to face, the outcomes of DINAMO represent another positive step forward in Boehringer Ingelheim and Lilly’s commitment to improve the lives of people living with cardio-renal and metabolic conditions such as type 2 diabetes.”
Reduction in HbA1c in participants treated with linagliptin was not statistically significant when compared with placebo. A numerical reduction of 0.34% (P=0.2935) was observed.1
The findings have been submitted for publication in a peer-reviewed journal.
Please click on the below link for further ‘Notes to editors’ and ‘References’:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221207005405/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Accertify and Liminal Release First Empirical Study Proving Fraud-Cyber Convergence Works - and Defining How to Do It Right22.7.2026 13:00:00 CEST | Press release
New research across 250 senior leaders identifies four organizational behaviors associated with a 3.4x performance advantage over siloed organizations Accertify, a leading fraud decisioning provider whose Predictive Yes Platform enables merchants to say yes to more good customers, more revenue, and more growth, today released The Convergence Dividend: Quantifying What Fraud-Cyber Convergence Actually Delivers, a landmark proprietary study conducted in partnership with Liminal. The research - spanning 250 Director-level and above fraud, risk, and security leaders across Retail/eCommerce, Travel, Restaurants/QSR, Entertainment & Media, and Marketplaces - is the first large-scale empirical proof that fraud-cyber convergence produces better business outcomes, and the first to identify the specific behaviors that separate top-performing organizations from the rest. While fraud-cyber convergence is a nearly unanimous (94%) recognized priority by respondents, the research found that many orga
New Visa Data Reveals How the FIFA World Cup 2026™ Created Pop-Up Economies Across Canada, Mexico and the United States22.7.2026 13:00:00 CEST | Press release
New Visa data reveals the FIFA World Cup 26™ drove a nearly 20% surge in cross-border transactions across host cities in Canada, Mexico and the United States. After the final whistle blew on the FIFA World Cup 2026™, millions of fans returned home with unforgettable memories and a trail of economic activity that stretched across countries. Every tap to pay left a lasting impact, as spending throughout the tournament delivered a meaningful boost to merchants and local economies across host cities in Canada, Mexico and the United States. According to new data from Visa, the tournament drove significant growth in cross-border spending, international travel, and digital commerce across host cities. The findings show how a major global event creates “pop-up economies,” defined by Visa as temporary, highly concentrated periods of commercial activity that emerge around major cultural, entertainment and sporting events. The data reveals that fans traveled from around the world to follow their
NIQ and Circle K Expand Global Analytics Collaboration Across More Than 12 Countries22.7.2026 12:00:00 CEST | Press release
Expanded agreement enables Circle K’s Business Units to accelerate smarter merchandising, pricing, and operational decisions across North America and Europe NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, and Circle K today announced a multi-year global agreement spanning more than 12 countries across North America and Europe. The collaboration brings together NIQ’s global scale, AI-powered analytics, and deep local market intelligence to help Circle K transform decision-making, accelerate growth, and deliver best-in-class customer experiences across its expanding global footprint. In an increasingly competitive and fast-changing retail landscape, the collaboration enables Circle K to stay ahead of evolving consumer demand, optimize performance, and unlock new growth opportunities across markets. Through NIQ’s AI-driven insights and decisioning platforms, Circle K’s Business Units and Global Center of Excellence will accelerate smarter merchandising, pricing, and operat
Japan's Cross-Border E-Commerce "WAFUU.COM" Unveils Official Mascot Character "Mochi"22.7.2026 10:00:00 CEST | Press release
A tiny happiness from Japan — WAFUU.COM introduces its new official character, Mochi, bringing more joy to fans around the world discovering Japanese products. QRESTIA Inc. (Headquarters: Shibuya, Tokyo; President & CEO: Hidemasa Fukada) is pleased to announce that WAFUU.COM, its cross-border e-commerce site, has unveiled its new official mascot character, Mochi. Mochi will represent WAFUU.COM's warmth and friendliness across its website, social media, campaigns, package inserts, and other creative materials, connecting with fans everywhere. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721435469/en/ Mochi, WAFUU.COM's new official mascot character, embodies "A tiny happiness from Japan." (Photo: WAFUU.COM) The debut video is now live on Mochi's official website: https://mochi.wafuu.com/ 1. About Mochi Mochi was born to embody the simple joy of choosing Japanese products. Its soft, rounded silhouette, gentle expression,
New NEURA Gym with RWTH Aachen: NEURA Robotics Expands its Global Training Network for Physical AI22.7.2026 09:10:00 CEST | Press release
NEURA Gym RWTH Aachen to open by end of 2026Ten NEURA Gyms under development, five operational by end of 2026 across Europe, the United States and ChinaIndustry partners gain access to the world’s first open infrastructure for training and deploying Physical AI NEURA Robotics ("NEURA"), the pioneer in cognitive robotics and creator of the Neuraverse, today announces a new partnership with RWTH Aachen University for the establishment of NEURA Gym RWTH Aachen. This continues the global rollout of NEURA Gyms, a worldwide network of purpose-built Physical AI training facilities that address the most significant barrier to intelligent robotics: the scarcity of real-world training data. The global rollout is backed by NEURA's Series C financing of up to $1.4 billion, the largest ever raised by a full-stack robotics company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721136838/en/ New NEURA Gym with RWTH Aachen: NEURA Roboti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom